查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1455696

非結核分枝桿菌市場，按藥物類別、配銷通路、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Nontuberculous Mycobacteria Market, By Drug Class, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 260 Pages | 商品交期: 2-3個工作天內

價格

報告要點

2023年非結核分枝桿菌市場規模為93.2034億美元，2024年至2032年複合CAGR為3.14%。

非結核分枝桿菌市場-市場動態

非結核分枝桿菌肺部疾病的發生率不斷增加，特別是在全球老年人口中，預計將推動市場的成長。

全球人口老化導致老年人數量顯著增加。由於年齡是 NTM 肺病的危險因素，預計老年人口的增加將導致該疾病發病率的上升，對診斷和治療解決方案產生更高的需求。醫療保健提供者和患者對 NTM 肺病認知的提高以及獲得醫療服務的機會的增加，導致診斷和治療率的提高。根據英國國家衛生服務局的資料，2021年，呼吸系統疾病（作為主要原因或相關原因）的死亡率在老年人中更為普遍（73%的呼吸道死亡發生在 75 歲及以上的人群中，而總死亡人數的比例為 67%）。此外，診斷技術的進步，例如高通量定序和增強培養方法，可能會為市場帶來成長機會。然而，高昂的治療成本可能會阻礙市場的成長。

非結核分枝桿菌市場 - 關鍵見解

根據研究分析師的分析，預計全球市場在預測期內（2024-2032年）每年將以 3.14%左右的CAGR成長

根據藥物類別細分，預計口服抗生素將在2023年顯示最大的市場佔有率

依地區分類，北美是2023年的主要收入來源

非結核分枝桿菌市場-細分分析：

全球非結核分枝桿菌市場依據藥物類別、配銷通路和區域進行細分。

根據藥物類別，市場分為四類：口服抗生素、靜脈注射抗生素、抗噁心藥物和霧化抗生素。口服抗生素類別在市場上佔有最大佔有率。 NTM 相關疾病的流行、現有抗生素的有效性、治療方案和監管授權等各種因素都會影響用於治療非結核分枝桿菌（NTM）感染的口服抗生素市場。

根據配銷通路，市場分為三個部分：醫院藥房、零售藥房和網路藥房。生產抗生素和其他治療 NTM 感染藥物的製藥公司透過傳統的藥品分銷管道分銷其產品。

非結核分枝桿菌市場 - 地理洞察

該市場在地理上遍佈各個地區，分別是北美、拉丁美洲、歐洲、亞太地區、中東和非洲。這些區域根據參與商業活動的國家進一步分類。預計該市場的成長將由北美主導，這主要是由於開發新藥物的研究力度加大以及醫療費用的上升。致力於發現 NTM 感染的新抗生素和治療方案的研發工作顯著激增。在美國，2021年醫療支出成長 2.7%，達到 4.3 兆美元，即人均 12, 914 美元。該成長率明顯低於美國醫學會表示的2020年（10.3%）。歐洲是該市場的第二大地區，這主要是由於傳染病發病率的上升。

非結核分枝桿菌市場-競爭格局：

專門開發抗生素和其他 NTM 感染治療藥物的各種製藥公司是該市場的主要競爭對手。他們根據產品有效性、安全性和定價等因素以及確保市場准入的策略進行競爭。競爭還可能包括創造對 NTM 物種具有更好活性的新抗生素或提高患者依從性和治療效果的配方。 NTM 市場的競爭延伸到臨床開發管道，公司的目標是推出新的治療方法或擴大現有產品的適應症。總體而言，NTM 市場的競爭由產品差異化、臨床開發工作、監管因素、市場准入計劃、研究和創新以及合作決定。

最近的發展：

2020年6月16日，Novartis ILARIS（canakinumab）獲得美國食品藥物管理局（FDA）核准用於治療成人史蒂爾氏症（AOSD）的新適應症。 FDA 核准治療 2 歲及以上的活動性史蒂爾症，包括系統性幼年特發性關節炎（SJIA）和 AOSD。

目錄

第1章 非結核分枝桿菌市場概述

  • 研究範圍
  • 市場預估年份

第2章 執行摘要

  • 市場摘要
    • 依藥物類別分類的非結核分枝桿菌市場摘要
    • 依配銷通路的非結核分枝桿菌市場摘要
    • 依國家分類的非結核分枝桿菌市場摘要
    • 依地區分類的非結核分枝桿菌市場摘要
  • 競爭洞察

第3章 非結核分枝桿菌主要市場趨勢

  • 非結核分枝桿菌市場促進因素
    • 市場促進因素的影響分析
  • 非結核分枝桿菌市場限制
    • 市場限制影響分析
  • 非結核分枝桿菌市場機會
  • 非結核分枝桿菌市場未來趨勢

第4章 非結核分枝桿菌產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章 非結核分枝桿菌市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第6章 非結核分枝桿菌市場格局

  • 2023年非結核分枝桿菌市佔率分析
  • 細分資料：按主要製造商
    • 既有參與者分析
    • 新興參與者分析

第7章 非結核分枝桿菌市場 - 依藥物類別

  • 概述
    • 依藥物類別分類的細分市場佔有率分析
    • 口服抗生素
    • 靜脈注射抗生素
    • 抗噁心
    • 吸入型抗生素

第8章 非結核分枝桿菌市場 - 依配銷通路

  • 概述
    • 依配銷通路分類的細分市場佔有率分析
    • 醫院藥房
    • 零售藥局
    • 網路藥局

第9章 非結核分枝桿菌市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美非結核分枝桿菌主要製造商
    • 北美市場規模和預測（依國家）
    • 北美市場規模和預測（依藥物類別）
    • 北美市場規模和預測（依配銷通路）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲非結核分枝桿菌主要製造商
    • 歐洲市場規模和預測（依國家）
    • 歐洲市場規模和預測（依藥物類別）
    • 歐洲市場規模和預測（依配銷通路）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區（APAC）
    • 概述
    • 亞太地區非結核分枝桿菌主要製造商
    • 亞太地區市場規模與預測（依國家）
    • 亞太地區市場規模和預測（依藥物類別）
    • 亞太地區市場規模和預測（依配銷通路）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲非結核分枝桿菌主要製造商
    • 拉丁美洲市場規模與預測（依國家）
    • 拉丁美洲市場規模與預測（依藥物類別）
    • 拉丁美洲市場規模和預測（依配銷通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲非結核分枝桿菌主要製造商
    • 中東和非洲市場規模及預測（依國家）
    • 中東和非洲市場規模及預測（依藥物類別）
    • 中東和非洲市場規模及預測（依配銷通路）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA的其他地區

第10章 主要供應商分析 - 非結核分枝桿菌產業

  • 競爭儀表板
  • 公司簡介
    • Insmed, RedHill Biopharma Ltd
    • Novartis AG
    • Paratek Pharmaceuticals Inc
    • Janssen
    • RevImmune
    • Nobelpharma Co Ltd
    • Others

第11章 360 度分析師視角

第12章 附錄

  • 研究方法論
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
Product Code: ANV2359

REPORT HIGHLIGHT

Nontuberculous Mycobacteria Market size was valued at USD 9,320.34 Million in 2023, expanding at a CAGR of 3.14% from 2024 to 2032.

Nontuberculous mycobacteria are a collection of bacteria that naturally exist in soil, water, and dust all over the world. Non-tuberculous mycobacteria (NTM) refers to a group of over 190 species of Mycobacterium, excluding Mycobacterium tuberculosis and Mycobacterium leprae. These microorganisms are present everywhere in the environment, especially in soil and water sources, and are increasingly being recognized as a cause of human diseases. Non-tuberculous mycobacteria can infect not only individuals with weakened immune systems but also those who are otherwise healthy. The diagnosis and management of NTM infections pose numerous challenges.

Nontuberculous Mycobacteria Market- Market Dynamics

Increasing occurrence of nontuberculous mycobacterial lung illness, particularly amongst the older population worldwide, is projected to propel market's growth.

The aging global population is experiencing a significant rise in the number of elderly individuals. Due to the fact that age is a risk factor for NTM lung disease, the increasing elderly demographic is anticipated to contribute to the growing incidence of the illness, thereby creating a higher demand for diagnostic and therapeutic solutions. The improved awareness among healthcare providers and patients regarding NTM lung disease, along with better access to healthcare services, has resulted in increased rates of diagnosis and treatment. According to the National Health Service, in 2021, the mortality rate from respiratory conditions (as either the primary or associated cause) was more prevalent among older individuals (73% of respiratory deaths occurred in individuals aged 75 and above, compared to 67% for total deaths). Additionally, advancements in diagnostic techniques, such as high-throughput sequencing and enhanced culture methods, could present growth opportunities for the market. Nevertheless, the high cost of treatment may impede the market's growth.

Nontuberculous Mycobacteria Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 3.14% over the forecast period (2024-2032)

Based on Drug Class segmentation, Oral Antibiotics was predicted to show maximum market share in the year 2023

On the basis of region, North America was the leading revenue generator in 2023

Nontuberculous Mycobacteria Market- Segmentation Analysis:

The Global Nontuberculous Mycobacteria Market is segmented on the basis of Drug Class, Distribution Channel, and Region.

The market is segmented into four categories according to Drug Class: Oral Antibiotics, IV Antibiotics, Anti-Nausea, and Nebulized Antibiotics. The Oral Antibiotics category holds the largest share in the market. Various factors such as the prevalence of NTM-related diseases, the effectiveness of existing antibiotics, treatment protocols, and regulatory authorizations impact the market for oral antibiotics utilized in treating nontuberculous mycobacteria (NTM) infections.

The market is categorized into three segments according to the Distribution Channel: Hospital pharmacies, Retail pharmacies, and online pharmacies. Pharmaceutical companies that manufacture antibiotics and other medications for NTM infections distribute their products through conventional pharmaceutical distribution channels.

Nontuberculous Mycobacteria Market- Geographical Insights

This market is geographically spread across various regions, namely North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided based on the countries involved in business activities. The growth of the market is expected to be dominated by North America, primarily due to the increased research efforts in developing new medications and the rising healthcare expenses. There is a notable surge in research and development endeavors focused on discovering new antibiotics and treatment regimens for NTM infections. In the United States, health spending witnessed a 2.7% increase in 2021, reaching USD4.3 trillion or USD12, 914 per capita. This growth rate is significantly lower than that of 2020 (10.3%), stated by the American Medical Association. Europe holds the second-largest region for this market, primarily due to the rising rates of infectious illnesses.

Nontuberculous Mycobacteria Market- Competitive Landscape:

Various pharmaceutical companies specializing in the development of antibiotics and other therapeutics for NTM infections are the main competitors in this market. They compete based on factors like product effectiveness, safety, and pricing, as well as strategies to secure market access. Competition may also involve creating new antibiotics with better activity against NTM species or formulations that improve patient adherence and outcomes. The rivalry in the NTM market extends to the clinical development pipeline, where companies aim to introduce new treatments or expand existing product indications. Overall, competition in the NTM market is shaped by product differentiation, clinical development efforts, regulatory factors, market access plans, research and innovation, and collaborations.

Recent Developments:

On June 16, 2020, Novartis ILARIS (canakinumab) was approved by the US Food and Drug Administration (FDA) for a new indication to treat Adult-Onset Still's Disease (AOSD). The FDA granted approval for active Still's disease, which includes both systemic juvenile idiopathic arthritis (SJIA) and AOSD, in patients aged 2 years and older.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Insmed, RedHill Biopharma Ltd

Novartis AG

Paratek Pharmaceuticals Inc

Janssen

RevImmune

Nobelpharma Co Ltd

Others

GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Oral Antibiotics
  • IV Antibiotics
  • Anti Nausea
  • Nebulized Antibiotics

GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

GLOBAL NONTUBERCULOUS MYCOBACTERIA MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1.Nontuberculous Mycobacteria Market Overview

  • 1.1.Study Scope
  • 1.2.Market Estimation Years

2.Executive Summary

  • 2.1.Market Snippet
    • 2.1.1.Nontuberculous Mycobacteria Market Snippet by Drug Class
    • 2.1.2.Nontuberculous Mycobacteria Market Snippet by Distribution Channel
    • 2.1.3.Nontuberculous Mycobacteria Market Snippet by Country
    • 2.1.4.Nontuberculous Mycobacteria Market Snippet by Region
  • 2.2.Competitive Insights

3.Nontuberculous Mycobacteria Key Market Trends

  • 3.1.Nontuberculous Mycobacteria Market Drivers
    • 3.1.1.Impact Analysis of Market Drivers
  • 3.2.Nontuberculous Mycobacteria Market Restraints
    • 3.2.1.Impact Analysis of Market Restraints
  • 3.3.Nontuberculous Mycobacteria Market Opportunities
  • 3.4.Nontuberculous Mycobacteria Market Future Trends

4.Nontuberculous Mycobacteria Industry Study

  • 4.1.PEST Analysis
  • 4.2.Porter's Five Forces Analysis
  • 4.3.Growth Prospect Mapping
  • 4.4.Regulatory Framework Analysis

5.Nontuberculous Mycobacteria Market: COVID-19 Impact Analysis

  • 5.1.Pre-COVID-19 Impact Analysis
  • 5.2.Post-COVID-19 Impact Analysis
    • 5.2.1.Top Performing Segments
    • 5.2.2.Marginal Growth Segments
    • 5.2.3.Top Looser Segments
    • 5.2.4.Marginal Loss Segments

6.Nontuberculous Mycobacteria Market Landscape

  • 6.1.Nontuberculous Mycobacteria Market Share Analysis, 2023
  • 6.2.Breakdown Data, by Key Manufacturer
    • 6.2.1.Established Players' Analysis
    • 6.2.2.Emerging Players' Analysis

7.Nontuberculous Mycobacteria Market - By Drug Class

  • 7.1.Overview
    • 7.1.1.Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 7.1.2.Oral Antibiotics
    • 7.1.3.IV Antibiotics
    • 7.1.4.Anti-Nausea
    • 7.1.5.Nebulized Antibiotics

8.Nontuberculous Mycobacteria Market - By Distribution Channel

  • 8.1.Overview
    • 8.1.1.Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 8.1.2.Hospital pharmacies
    • 8.1.3.Retail pharmacies
    • 8.1.4.Online pharmacies

9.Nontuberculous Mycobacteria Market- By Geography

  • 9.1.Introduction
    • 9.1.1.Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 9.2.North America
    • 9.2.1.Overview
    • 9.2.2.Nontuberculous Mycobacteria Key Manufacturers in North America
    • 9.2.3.North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.2.4.North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.2.5.North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.2.6.U.S.
      • 9.2.6.1.Overview
      • 9.2.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.6.3.U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.2.6.4.U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.2.7.Canada
      • 9.2.7.1.Overview
      • 9.2.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.7.3.Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.2.7.4.Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.3.Europe
    • 9.3.1.Overview
    • 9.3.2.Nontuberculous Mycobacteria Key Manufacturers in Europe
    • 9.3.3.Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.3.4.Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.3.5.Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.6.Germany
      • 9.3.6.1.Overview
      • 9.3.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.6.3.Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.3.6.4.Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.7.Italy
      • 9.3.7.1.Overview
      • 9.3.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.7.3.Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.3.7.4.Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.8.United Kingdom
      • 9.3.8.1.Overview
      • 9.3.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.8.3.United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.3.8.4.United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.9.France
      • 9.3.9.1.Overview
      • 9.3.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.9.3.France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.3.9.4.France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.10.Russia
      • 9.3.10.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.10.2.Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.3.10.3.Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.11.Netherlands
      • 9.3.11.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.11.2.Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.3.11.3.Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.12.Sweden
      • 9.3.12.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.12.2.Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.3.12.3.Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.13.Poland
      • 9.3.13.1.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.13.2.Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.3.13.3.Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.3.14.Rest of Europe
      • 9.3.14.1.Overview
      • 9.3.14.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.14.3.Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.3.14.4.Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.4.Asia Pacific (APAC)
    • 9.4.1.Overview
    • 9.4.2.Nontuberculous Mycobacteria Key Manufacturers in Asia Pacific
    • 9.4.3.Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.4.4.Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.4.5.Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.6.India
      • 9.4.6.1.Overview
      • 9.4.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.6.3.India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.4.6.4.India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.7.China
      • 9.4.7.1.Overview
      • 9.4.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.7.3.China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.4.7.4.China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.8.Japan
      • 9.4.8.1.Overview
      • 9.4.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.8.3.Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.4.8.4.Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.9.South Korea
      • 9.4.9.1.Overview
      • 9.4.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.9.3.South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.4.9.4.South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.10.Australia
      • 9.4.10.1.Overview
      • 9.4.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.10.3.Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.4.10.4.Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.11.Thailand
      • 9.4.11.1.Overview
      • 9.4.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.11.3.Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.4.11.4.Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.12.Indonesia
      • 9.4.12.1.Overview
      • 9.4.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.12.3.Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.4.12.4.Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.13.Philippines
      • 9.4.13.1.Overview
      • 9.4.13.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.13.3.Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.4.13.4.Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.4.14.Rest of APAC
      • 9.4.14.1.Overview
      • 9.4.14.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.14.3.Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.4.14.4.Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.5.Latin America
    • 9.5.1.Overview
    • 9.5.2.Nontuberculous Mycobacteria Key Manufacturers in Latin America
    • 9.5.3.Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.5.4.Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.5.5.Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.5.6.Brazil
      • 9.5.6.1.Overview
      • 9.5.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.6.3.Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.5.6.4.Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.5.7.Mexico
      • 9.5.7.1.Overview
      • 9.5.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.7.3.Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.5.7.4.Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.5.8.Argentina
      • 9.5.8.1.Overview
      • 9.5.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.8.3.Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.5.8.4.Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.5.9.Colombia
      • 9.5.9.1.Overview
      • 9.5.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.9.3.Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.5.9.4.Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.5.10.Rest of LATAM
      • 9.5.10.1.Overview
      • 9.5.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.10.3.Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.5.10.4.Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 9.6.Middle East and Africa
    • 9.6.1.Overview
    • 9.6.2.Nontuberculous Mycobacteria Key Manufacturers in Middle East and Africa
    • 9.6.3.Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.6.4.Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 9.6.5.Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.6.Saudi Arabia
      • 9.6.6.1.Overview
      • 9.6.6.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.6.3.Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.6.6.4.Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.7.United Arab Emirates
      • 9.6.7.1.Overview
      • 9.6.7.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.7.3.United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.6.7.4.United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.8.Israel
      • 9.6.8.1.Overview
      • 9.6.8.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.8.3.Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.6.8.4.Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.9.Turkey
      • 9.6.9.1.Overview
      • 9.6.9.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.9.3.Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.6.9.4.Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.10.Algeria
      • 9.6.10.1.Overview
      • 9.6.10.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.10.3.Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.6.10.4.Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.11.Egypt
      • 9.6.11.1.Overview
      • 9.6.11.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.11.3.Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.6.11.4.Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 9.6.12.Rest of MEA
      • 9.6.12.1.Overview
      • 9.6.12.2.Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.12.3.Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 9.6.12.4.Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

10.Key Vendor Analysis- Nontuberculous Mycobacteria Industry

  • 10.1.Competitive Dashboard
  • 10.2.Company Profiles
    • 10.2.1.Insmed, RedHill Biopharma Ltd
    • 10.2.2.Novartis AG
    • 10.2.3.Paratek Pharmaceuticals Inc
    • 10.2.4.Janssen
    • 10.2.5.RevImmune
    • 10.2.6.Nobelpharma Co Ltd
    • 10.2.7.Others

11.360 Degree Analyst View

12.Appendix

  • 12.1.Research Methodology
  • 12.2.References
  • 12.3.Abbreviations
  • 12.4.Disclaimer
  • 12.5.Contact Us

List of Tables

  • TABLE List of data Drug Classs
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Nontuberculous Mycobacteria Market: Drug Class Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Class
  • TABLE Global Nontuberculous Mycobacteria Market, by Drug Class 2019-2032 (USD Million)
  • TABLE Nontuberculous Mycobacteria Market: Distribution Channel Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Global Nontuberculous Mycobacteria Market, by Distribution Channel 2019-2032 (USD Million)
  • TABLE Nontuberculous Mycobacteria Market: Regional snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Nontuberculous Mycobacteria Market, by Region 2019-2032 (USD Million)
  • TABLE North America Nontuberculous Mycobacteria Market, by Country, 2019-2032 (USD Million)
  • TABLE North America Nontuberculous Mycobacteria Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE North America Nontuberculous Mycobacteria Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Europe Nontuberculous Mycobacteria Market, by Country, 2019-2032 (USD Million)
  • TABLE Europe Nontuberculous Mycobacteria Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Europe Nontuberculous Mycobacteria Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Asia Pacific Nontuberculous Mycobacteria Market, by Country, 2019-2032 (USD Million)
  • TABLE Asia Pacific Nontuberculous Mycobacteria Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Asia Pacific Nontuberculous Mycobacteria Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Latin America Nontuberculous Mycobacteria Market, by Country, 2019-2032 (USD Million)
  • TABLE Latin America Nontuberculous Mycobacteria Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Latin America Nontuberculous Mycobacteria Market, by Distribution Channel, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Nontuberculous Mycobacteria Market, by Country, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Nontuberculous Mycobacteria Market, by Drug Class, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Nontuberculous Mycobacteria Market, by Distribution Channel, 2019-2032 (USD Million)

List of Figures

  • FIGURE Nontuberculous Mycobacteria Market Segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2023
  • FIGURE Drug Class segment market share analysis, 2023 & 2032
  • FIGURE Drug Class segment market size forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Distribution Channel segment market share analysis, 2023 & 2032
  • FIGURE Distribution Channel segment market size forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Regional segment market share analysis, 2023 & 2032
  • FIGURE Regional segment market size forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE North America Nontuberculous Mycobacteria Market share and leading players, 2023
  • FIGURE Europe Nontuberculous Mycobacteria Market share and leading players, 2023
  • FIGURE Asia Pacific Nontuberculous Mycobacteria Market share and leading players, 2023
  • FIGURE Latin America Nontuberculous Mycobacteria Market share and leading players, 2023
  • FIGURE Middle East and Africa Nontuberculous Mycobacteria Market share and leading players, 2023
  • FIGURE North America market share analysis by country, 2023
  • FIGURE U.S. Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Canada Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Europe Nontuberculous Mycobacteria Market share analysis by country, 2023
  • FIGURE Germany Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Spain Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Italy Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE France Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE UK Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Russia Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Netherlands Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Sweden Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Poland Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Rest of the Europe Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Asia Pacific Nontuberculous Mycobacteria Market share analysis by country, 2023
  • FIGURE India Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE China Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Japan Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE South Korea Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Australia Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Thailand Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Indonesia Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Phillipines Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Rest of APAC Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Latin America Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Latin America Nontuberculous Mycobacteria Market share analysis by country, 2023
  • FIGURE Brazil Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Mexico Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Argentina Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Colombia Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Rest of LATAM Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Middle East and Africa Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Middle East and Africa Nontuberculous Mycobacteria Market share analysis by country, 2023
  • FIGURE Saudi Arabia Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE United Arab Emirates Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Israel Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Turkey Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Algeria Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Egypt Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Rest of MEA Nontuberculous Mycobacteria Market size, forecast and trend analysis, 2019 to 2032 (USD Million)